Search - tctmd.com

Displaying 201 - 220 of 409

Sort: Relevancy | Date

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

News Daily News

More Insights Into AAA Genetics Spur New Questions on Screening

Caitlin E. Cox

September 29, 2020

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

News Daily News

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Yael L. Maxwell

September 14, 2020

News Conference News ESC 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Yael L. Maxwell

September 02, 2020

News Daily News

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Yael L. Maxwell

August 27, 2020

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Daily News

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

L.A. McKeown

August 04, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

A secondary analysis from ASPREE sets up two large RCTs testing statins in an elderly primary-prevention population.

News Daily News

Statins Cut CV Risk but Don’t Boost Disability-Free Survival in Healthy Elderly

Michael O'Riordan

July 06, 2020

News Daily News

AHA: Increased Diabetes, CVD Risk for American Indians, Alaskan Natives

Yael L. Maxwell

May 29, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Advertisement

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

More Insights Into AAA Genetics Spur New Questions on Screening

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Statins Cut CV Risk but Don’t Boost Disability-Free Survival in Healthy Elderly

AHA: Increased Diabetes, CVD Risk for American Indians, Alaskan Natives

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content